Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
29.50
-0.59 (-1.98%)
Aug 14, 2025, 11:37 AM - Market open
Crinetics Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 53.73 | 264.55 | 54.9 | 32.67 | 200.7 | 93.09 | Upgrade
|
| Short-Term Investments | 1,143 | 1,090 | 503.66 | 301.75 | 133.01 | 77.79 | Upgrade
|
| Cash & Short-Term Investments | 1,196 | 1,354 | 558.56 | 334.43 | 333.71 | 170.88 | Upgrade
|
| Cash Growth | 38.64% | 142.42% | 67.02% | 0.21% | 95.29% | 44.33% | Upgrade
|
| Other Receivables | - | 8.47 | 9.26 | 2.9 | 1.48 | 1.83 | Upgrade
|
| Receivables | - | 8.47 | 9.26 | 2.9 | 1.48 | 1.83 | Upgrade
|
| Prepaid Expenses | 20.4 | 10.43 | 4.56 | 3.51 | 7.2 | 1.72 | Upgrade
|
| Restricted Cash | 0.5 | 0.5 | - | - | - | - | Upgrade
|
| Other Current Assets | - | 1.92 | 1.78 | 4.36 | 2.34 | 3.06 | Upgrade
|
| Total Current Assets | 1,217 | 1,375 | 574.15 | 345.18 | 344.72 | 177.49 | Upgrade
|
| Property, Plant & Equipment | 56.57 | 55.58 | 57.43 | 4.99 | 4.72 | 5.41 | Upgrade
|
| Long-Term Investments | - | 2 | 0.47 | - | 1.01 | - | Upgrade
|
| Other Long-Term Assets | 15.74 | 1.63 | 3.3 | 2.01 | 0.57 | 0.54 | Upgrade
|
| Total Assets | 1,290 | 1,435 | 635.35 | 352.18 | 351.02 | 183.45 | Upgrade
|
| Accounts Payable | 11.33 | 5.85 | 6.55 | 6.88 | 3.42 | 3.49 | Upgrade
|
| Accrued Expenses | 48.56 | 44.49 | 27.35 | 17.19 | 11.63 | 6.17 | Upgrade
|
| Current Portion of Leases | 6.61 | 7.15 | 4.17 | 1.05 | 0.94 | 0.84 | Upgrade
|
| Current Unearned Revenue | 1.9 | 2.18 | 2.06 | 2.24 | - | - | Upgrade
|
| Other Current Liabilities | - | 0.01 | 3.82 | 0.36 | - | - | Upgrade
|
| Total Current Liabilities | 68.4 | 59.68 | 43.94 | 27.72 | 16 | 10.49 | Upgrade
|
| Long-Term Leases | 43.33 | 44.57 | 47.56 | 2.02 | 3.07 | 4.01 | Upgrade
|
| Long-Term Unearned Revenue | 3.99 | 4.7 | 4.75 | 6.1 | - | - | Upgrade
|
| Other Long-Term Liabilities | 2.33 | 0.83 | - | - | 0 | 0.02 | Upgrade
|
| Total Liabilities | 118.05 | 109.79 | 96.25 | 35.85 | 19.07 | 14.53 | Upgrade
|
| Common Stock | 2,335 | 2,276 | 1,192 | 759.43 | 607.58 | 336.51 | Upgrade
|
| Retained Earnings | -1,165 | -952.11 | -653.7 | -439.17 | -275.26 | -167.61 | Upgrade
|
| Comprehensive Income & Other | 1.51 | 0.96 | 0.98 | -3.93 | -0.38 | 0.03 | Upgrade
|
| Total Common Equity | 1,172 | 1,325 | 539.11 | 316.33 | 331.94 | 168.92 | Upgrade
|
| Shareholders' Equity | 1,172 | 1,325 | 539.11 | 316.33 | 331.94 | 168.92 | Upgrade
|
| Total Liabilities & Equity | 1,290 | 1,435 | 635.35 | 352.18 | 351.02 | 183.45 | Upgrade
|
| Total Debt | 49.94 | 51.72 | 51.73 | 3.08 | 4.01 | 4.85 | Upgrade
|
| Net Cash (Debt) | 1,146 | 1,302 | 506.83 | 331.35 | 329.69 | 166.03 | Upgrade
|
| Net Cash Growth | 41.60% | 156.96% | 52.96% | 0.50% | 98.57% | 47.17% | Upgrade
|
| Net Cash Per Share | 12.79 | 16.12 | 8.73 | 6.37 | 8.58 | 5.45 | Upgrade
|
| Filing Date Shares Outstanding | 94.18 | 93.05 | 69.6 | 53.91 | 47.78 | 33.03 | Upgrade
|
| Total Common Shares Outstanding | 94.13 | 92.93 | 68.18 | 53.88 | 47.6 | 33 | Upgrade
|
| Working Capital | 1,149 | 1,316 | 530.21 | 317.46 | 328.73 | 167 | Upgrade
|
| Book Value Per Share | 12.45 | 14.26 | 7.91 | 5.87 | 6.97 | 5.12 | Upgrade
|
| Tangible Book Value | 1,172 | 1,325 | 539.11 | 316.33 | 331.94 | 168.92 | Upgrade
|
| Tangible Book Value Per Share | 12.45 | 14.26 | 7.91 | 5.87 | 6.97 | 5.12 | Upgrade
|
| Machinery | 10.96 | 7.9 | 6.11 | 4.07 | 2.79 | 2.25 | Upgrade
|
| Leasehold Improvements | 13.3 | 11.9 | 9.84 | 3.52 | 3.52 | 3.49 | Upgrade
|
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.